-
Clinical approval of recombinant human mouse chimeric anti-CD20 monoclonal antibody injection
Time of Update: 2020-04-03
According to the website of the State Food and drug administration, the approval status of the recombinant human mouse chimeric anti-CD20 monoclonal antibody injection (cxsl1100072
-
Xinda biology and adimab cooperate to develop therapeutic antibody
Time of Update: 2020-04-03
On August 20, Cinda biopharmaceutical (Suzhou) Co., Ltd. announced that it has signed a development and commercialization plan for therapeutic antibody with adimab company of the United States.
-
Application for clinical acceptance of recombinant anti HER2 humanized monoclonal antibody for injection in uniform pharmaceutical
Time of Update: 2020-04-03
Whether the above new drug application of Wanle pharmaceutical can pass the clinical review and obtain the approval document is uncertain, and there is great uncertainty in the approval progress and results.
-
Xikang cooperates with afinita biotech to develop new anti-cancer monoclonal antibody drugs
Time of Update: 2020-04-03
Xikang will provide cell line development, process development, mass production and other professional technologies for afinita biotech anti-cancer monoclonal antibody new drugs with its plant facilities in Zhubei, Taiwan and Wuhan, China.
-
Wanfu biological new coronavirus antibody rapid detection reagent quickly approved for market
Time of Update: 2020-04-03
The novel coronavirus (2019-nCoV) antibody kit (colloidal gold) was developed by the Guangzhou Wanfu biotechnology Limited by Share Ltd in February 23rd
It has obtained
-
Haizheng pharmaceutical "recombinant human mouse chimeric anti-CD20 monoclonal antibody injection" obtained clinical approval
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA), the approval status of "recombinant human mouse chimeric anti-CD20 monoclonal antibody injection", a clinical heavyweight McAb drug declared by Haizheng pharmaceutical, has changed to "approved pending".
-
Guilin Sanjin Pharmaceutical Co., Ltd. obtained approval for clinical trial on recombinant anti EGFR human mouse chimeric monoclonal antibody injection
Time of Update: 2020-04-03
Next, the company will carry out the clinical trial study of recombinant anti EGFR human mouse chimeric monoclonal antibody injection as soon as possible in accordance with the requirements of the above-mentioned drug clinical approval documents.
-
CITIC Guojian's "Herceptin" monoclonal antibody generic cypriotin obtained clinical approval
Time of Update: 2020-04-03
The pace of approval of mAbs is accelerating
On the morning of May 30, the State Administration of food and Drug Administration reported that the approval status
-
All human monoclonal antibody injection of Watson biological recombinant anti TNF - α obtained the approval of clinical trial in Korea
Time of Update: 2020-04-03
Jiahe biopharmaceutical Co., Ltd., a subsidiary of Watson biology, has obtained the clinical trial approval document issued by the Ministry of food and drug safety of South Korea
-
Clinical approval of recombinant human anti TNF α monoclonal antibody for injection
Time of Update: 2020-04-03
Jiankangyuan and Lizhu group's joint-venture subsidiary announced today (March 7) that Zhuhai Lizhu monoclonal antibody Biotechnology Co., Ltd
(hereinafter referred
-
Heavyweight: 100 Xinyi provides 2019 ncov full set of antibodies - and is humanized
Time of Update: 2020-04-03
In order to achieve this method, four core materials and at least one germplasm control product are needed, i.e. antigen, gold standard detection antibody, c-line antibody and quality control positive antibody.
-
Fuhong Hanlin, a subsidiary of Fosun Pharmaceutical, obtained the first clinical approval for monoclonal antibody drugs
Time of Update: 2020-04-03
This approval is the first clinical approval of Fuhong Hanlin since its establishment, and also the first clinical approval of monoclonal antibody drugs obtained by Fosun Pharmaceutical holding member enterprises.
-
Zhong Nanshan: novel coronavirus pneumonia is approved by two antibody kits
Time of Update: 2020-04-03
China's novel coronavirus pneumonia has also been approved by the State Administration of drug administration, one of which is a reagent for identifying influenza, new crown pneumonia and parainfluenza, "Zhong Nan Shan said." this is a key task.
-
Yiteng pharmaceutical and Ablynx reached a cooperation agreement on the nanotherapy antibody alx-0141 for osteoporosis
Time of Update: 2020-04-03
Yiteng pharmaceutical was authorized by Ablynx pharmaceutical to develop, register and commercialize its nano antibody product alx-0141 in mainland China, Hong Kong, Macao and Taiwan, which is mainly used for indications such as osteoporosis and cancer bone metastasis.
-
The "National Key Laboratory for antibody drug development" built by Huabei pharmaceutical new drug research and development company passed the expert acceptance organized by the Ministry of science and technology
Time of Update: 2020-04-03
On January 13, the Ministry of science and technology organized an acceptance expert group composed of nine experts in the field of drug research and development to carry out
-
Drug Ming biology and novel coronavirus antibody Vir reach global R & D cooperation
Time of Update: 2020-02-26
25 novel coronavirus and Biotech Corp Vir Biotechnology (hereinafter referred to as Vir) announced that the two sides reached a cooperation agreement for the development
-
Zhong Nanshan: novel coronavirus pneumonia is approved by two antibody kits
Time of Update: 2020-02-24
China's novel coronavirus pneumonia has also been approved by the State Administration of drug administration, one of which is a reagent for identifying influenza, new crown pneumonia and parainfluenza, "Zhong Nan Shan said." this is a key task.
-
Essence pharmaceuticals terminates the development of two human monoclonal antibody products
Time of Update: 2020-02-20
In the evening of February 19th, the essence pharmaceutical announced that it signed the cooperation and authorization agreement with Kadmon Corporation and LLC in October 29, 2015
-
Science subjournal: tumor specific antibody targeted inhibition of Ras mutant tumors
Time of Update: 2020-02-20
Injecting inras37 into mice with small rasmut xenograft tumor by systemic administration can produce strong antitumor activity, but this antibody has little effect on the downstream rasmut tumor with simultaneous PI3K mutation, which can be overcome by combining PI3K inhibitor.
-
First in China, approved clinical application of Lizhu pharmaceutical's monoclonal antibody IL-17A / F
Time of Update: 2020-02-20
The recombinant anti-human IL-17A / F humanized monoclonal antibody injection can simultaneously target the homologous dimer il-17a-a and il-17f-f, as well as the heterodimer il-17a-f.
